Endocrine ophthalmopathy – Treatment

Go back

Endocrine ophthalmopathy is an autoimmune condition that affects the tissues around the eyes, causing swelling, inflammation, and a range of visual and cosmetic changes. Though it can seem overwhelming, understanding the condition and the available treatments can help patients take control of their health journey and protect their vision and quality of life.

Understanding Treatment Options for Eye Health in Autoimmune Thyroid Disease

Managing endocrine ophthalmopathy, also known as thyroid eye disease or Graves’ orbitopathy, involves a careful balance between treating symptoms, controlling the disease’s active phase, and preserving both vision and appearance. The primary goals of treatment include reducing inflammation, preventing damage to the eye and optic nerve, improving comfort, and addressing any changes in how the eyes look and function. Because this condition affects each person differently, treatments are chosen based on the severity of symptoms, the activity level of the disease, and how it impacts daily life.[1]

This eye condition occurs most commonly in people with Graves’ disease, an autoimmune disorder that causes the thyroid to produce too much hormone. About one-third of people with Graves’ disease develop some signs or symptoms of thyroid eye disease, though only about 5% experience moderate to severe forms of the condition. The disease tends to go through an active phase lasting about nine to twelve months, during which inflammation is most pronounced, before gradually settling into a stable, inactive phase.[3][4]

Treatment decisions depend heavily on which phase the disease is in. During the active phase, the main focus is on reducing inflammation and preventing long-term damage. Once the disease becomes inactive, attention shifts toward repairing any lasting changes through surgical procedures if needed. It’s also critical to keep thyroid hormone levels stable throughout the course of the disease, as fluctuations in thyroid hormones—whether too high or too low—can worsen eye symptoms.[1]

⚠️ Important
Maintaining stable thyroid hormone levels is essential for people with thyroid eye disease. Both an overactive thyroid and an untreated underactive thyroid can trigger worsening of eye symptoms. If you undergo radioactive iodine therapy to treat hyperthyroidism, your doctor will need to monitor your thyroid levels closely afterward to avoid hypothyroidism, which can make the eye condition worse.

Standard Treatment Methods for Thyroid Eye Disease

For many people with mild symptoms, supportive care is often sufficient. This includes measures to relieve discomfort and protect the eyes from damage. Artificial tears and lubricating eye drops are used throughout the day to combat dryness and the gritty sensation that many patients describe as feeling like sand in their eyes. These drops help keep the surface of the eye moist, especially in cases where the eyelids are pulled back and cannot fully close. At night, lubricating gels or ointments provide longer-lasting protection. Wearing sunglasses outdoors shields the eyes from wind, dust, and bright light, all of which can worsen irritation.[3][5]

Patients are also advised to sleep with the head of the bed elevated, which helps reduce swelling around the eyes overnight. Cool compresses applied to closed eyelids can ease puffiness and discomfort. These simple self-care strategies can significantly improve comfort and prevent complications like corneal exposure, a condition where the front surface of the eye becomes damaged due to inadequate moisture and protection.[6][12]

Smoking cessation is one of the most important interventions for anyone with thyroid eye disease. Smoking is a major modifiable risk factor that makes the condition more severe and resistant to treatment. It reduces blood flow to the tissues, causing them to receive less oxygen, which worsens inflammation and swelling. Patients who smoke are strongly encouraged to quit, and even exposure to secondhand smoke should be avoided.[6][12]

Steroid Therapy for Active Inflammation

Corticosteroids are the first-line treatment for moderate to severe active thyroid eye disease. These powerful anti-inflammatory drugs work by suppressing the immune system’s attack on the tissues around the eyes. Steroids can be given in several forms depending on the severity of symptoms. For mild inflammation, steroid eye drops may be sufficient. In more serious cases, high-dose oral steroids or intravenous steroids are used to quickly bring down swelling and prevent progression.[3][8]

Intravenous steroid therapy is often preferred over oral steroids because it tends to be more effective and causes fewer side effects. The typical regimen involves weekly infusions given over several weeks. While steroids are highly effective at reducing symptoms during the active phase, they do not change the overall duration of the disease or prevent it from eventually entering the inactive phase. Their role is to manage inflammation and protect vision during the critical early period.[8][11]

However, steroid treatment is not without risks. Common side effects include weight gain, mood changes, elevated blood sugar levels, increased blood pressure, and a higher risk of infections. Long-term use can lead to bone thinning and an increased risk of fractures. For this reason, doctors carefully weigh the benefits and risks when prescribing steroids and monitor patients closely throughout treatment.[3]

Orbital Radiotherapy

Radiation therapy directed at the tissues behind the eyes is another treatment option, especially when combined with steroids. Low-dose radiation helps reduce inflammation by targeting the immune cells that are attacking the orbital tissues. This treatment is typically given over several sessions and is most effective during the active phase of the disease. Radiotherapy is particularly helpful for patients with eye muscle problems that cause double vision.[3][12]

The procedure is generally well tolerated, but potential side effects include temporary worsening of symptoms, dry eyes, and, rarely, damage to the retina or optic nerve. Because of concerns about radiation exposure, this treatment is usually reserved for adults and is not used in children or young adults.[3]

Surgical Interventions

Once the disease has entered the inactive phase and inflammation has settled, surgery may be needed to correct lasting changes. There are several types of surgical procedures used in thyroid eye disease, and they are often performed in a specific order to achieve the best results.[4]

Orbital decompression surgery is performed when the eyes remain bulging after the active phase ends. This procedure involves removing some of the bone and fat from the eye socket to create more room for the swollen tissues, allowing the eye to sit back in a more normal position. Decompression surgery can also relieve pressure on the optic nerve in cases where vision is threatened by nerve compression. This operation carries risks including double vision, changes in vision, and scarring.[3][4]

Strabismus surgery corrects misalignment of the eyes caused by scarring or stiffness in the eye muscles. This type of surgery is usually done after decompression surgery, if needed, and aims to restore proper eye movement and eliminate double vision. Multiple surgeries may be required to achieve the best alignment.[4]

Eyelid surgery is often the final step in the surgical treatment sequence. Procedures can lengthen retracted eyelids, allowing them to close properly and protect the eye. Blepharoplasty, or eyelid surgery, can also remove excess skin and fat to improve the appearance of puffy or baggy eyelids. These cosmetic and functional improvements can have a significant impact on a patient’s quality of life and self-esteem.[4]

Emerging Therapies and Clinical Trials

Research into thyroid eye disease has advanced significantly in recent years, leading to the development of new treatment approaches that target specific pathways involved in the immune response. Clinical trials have explored various innovative therapies, offering hope for patients who do not respond well to conventional treatments.[8]

Biologic Therapies and Immunomodulators

One of the most promising developments in thyroid eye disease treatment is the use of biologic medications that target specific components of the immune system. These drugs are designed to block the signals that drive inflammation and tissue damage in the orbital area. Unlike broad immunosuppressants like steroids, biologics work more selectively, which may reduce side effects.[8]

Teprotumumab is a biologic medication that has shown remarkable results in clinical trials for active, moderate to severe thyroid eye disease. This drug is an antibody that blocks the insulin-like growth factor-1 receptor (IGF-1R), which plays a key role in the inflammation and tissue expansion that occurs in thyroid eye disease. In Phase II and Phase III clinical trials, teprotumumab significantly reduced eye bulging, improved double vision, and decreased inflammation in a high percentage of patients. The treatment is given as an intravenous infusion every three weeks for a total of eight infusions.[8][11]

In the trials, patients receiving teprotumumab showed substantial reductions in proptosis—the medical term for bulging eyes—compared to those receiving placebo. Many patients also experienced improvements in their quality of life and a reduction in the clinical activity of the disease. Side effects reported in trials included muscle spasms, nausea, hair loss, diarrhea, fatigue, and high blood sugar levels. Because of its effectiveness, teprotumumab has been approved in some countries for the treatment of active thyroid eye disease.[8][11]

Other biologic agents being studied include drugs that target different immune pathways. Rituximab, a drug that depletes a type of immune cell called B cells, has been tested in small studies with mixed results. Some patients showed improvement in eye symptoms, while others did not respond. Further research is needed to determine which patients might benefit most from this approach.[8]

Immunosuppressive Medications

For patients who cannot tolerate steroids or who do not respond adequately to them, other immunosuppressive drugs may be used. Medications such as methotrexate, azathioprine, and mycophenolate mofetil have been tried in thyroid eye disease, often in combination with steroids. These drugs work by broadly suppressing the immune system, which can help reduce inflammation in the eye tissues. However, their effectiveness in thyroid eye disease is not as well established as that of steroids, and they carry their own risks of side effects, including liver toxicity, bone marrow suppression, and increased infection risk.[3][8]

Somatostatin Analogues

Somatostatin analogues are drugs that mimic a natural hormone and have been explored as a potential treatment for thyroid eye disease. These medications, which include octreotide and lanreotide, work by binding to receptors found on the surface of cells in the orbital tissues. Early studies suggested that these drugs might reduce inflammation and swelling, but larger clinical trials have not consistently demonstrated significant benefits. As a result, somatostatin analogues are not commonly used in standard practice but may be considered in select cases, particularly when other treatments have failed.[3]

Intravenous Immunoglobulin and Plasmapheresis

Intravenous immunoglobulin (IVIG) is a treatment that involves infusing antibodies collected from donated blood into the patient’s bloodstream. This therapy can help modulate the immune system and has been used in various autoimmune diseases. Some case reports and small studies have suggested potential benefits in thyroid eye disease, but the evidence remains limited, and IVIG is generally reserved for severe cases that do not respond to other treatments.[3]

Plasmapheresis, a procedure that filters the blood to remove harmful antibodies, has also been explored as a treatment option. However, like IVIG, evidence supporting its use is limited, and it is not widely used due to the availability of more effective therapies.[3]

Clinical Trial Phases and Patient Eligibility

Clinical trials for thyroid eye disease follow a structured process. Phase I trials focus on safety, testing new drugs in a small number of healthy volunteers or patients to determine safe doses and identify side effects. Phase II trials evaluate the effectiveness of the treatment in a larger group of patients with the disease, looking at whether the drug improves symptoms and whether it is safe enough to continue testing. Phase III trials compare the new treatment to standard treatments or placebo in large groups of patients to confirm its effectiveness, monitor side effects, and gather information to allow the drug to be used safely. Finally, Phase IV trials occur after a drug has been approved and are used to monitor long-term effectiveness and safety in the general population.[8]

Clinical trials for thyroid eye disease are conducted at medical centers around the world, including locations in the United States, Europe, and other regions. Patients interested in participating in a trial should speak with their healthcare provider to determine if they meet eligibility criteria, which often include having active, moderate to severe disease and not responding adequately to conventional treatments.[11]

Most Common Treatment Methods

  • Supportive Care and Symptom Management
    • Artificial tears and lubricating eye drops throughout the day to relieve dryness and irritation
    • Lubricating gels or ointments at night for longer-lasting moisture
    • Cool compresses applied to closed eyelids to reduce swelling
    • Elevating the head of the bed during sleep to minimize eye puffiness
    • Wearing sunglasses outdoors to protect eyes from wind, light, and dust
    • Smoking cessation to reduce disease severity and improve treatment response
  • Anti-Inflammatory Medical Therapy
    • High-dose corticosteroids given intravenously or orally to reduce inflammation during the active phase
    • Steroid eye drops for mild inflammatory symptoms
    • Immunosuppressive drugs such as methotrexate, azathioprine, or mycophenolate mofetil for patients who cannot tolerate steroids
  • Radiation Therapy
    • Low-dose orbital radiotherapy combined with steroids to reduce inflammation in the tissues behind the eyes
    • Particularly effective for treating eye muscle involvement and double vision
  • Biologic Therapies
    • Teprotumumab, an antibody that blocks the IGF-1 receptor, shown to reduce eye bulging and improve double vision in clinical trials
    • Rituximab, a drug that depletes B cells, tested in small studies with mixed results
  • Surgical Interventions
    • Orbital decompression surgery to create more space in the eye socket and reduce eye bulging
    • Strabismus surgery to correct eye muscle misalignment and eliminate double vision
    • Eyelid surgery to correct eyelid retraction and improve eye closure and appearance
    • Blepharoplasty to remove excess skin and fat from puffy eyelids
  • Other Therapies Under Investigation
    • Somatostatin analogues such as octreotide and lanreotide, which bind to receptors on orbital tissue cells
    • Intravenous immunoglobulin (IVIG) to modulate the immune response in severe cases
    • Plasmapheresis to filter harmful antibodies from the blood

Living With Thyroid Eye Disease

Beyond medical and surgical treatments, adapting daily life to manage symptoms is an important part of living with thyroid eye disease. Making changes to the home and work environment can improve safety and comfort. For example, rearranging furniture to eliminate tripping hazards and using nightlights in hallways can help navigate spaces more safely if vision changes occur. Positioning computer screens at eye level and using anti-glare filters can reduce eye strain. Using humidifiers indoors can keep the air moist and prevent dry eyes, especially during winter months.[14]

Patients with double vision may benefit from special prism glasses prescribed by an eye specialist. These glasses can help align images and reduce the discomfort of seeing two of everything. Assistive devices such as magnifying glasses or electronic screen magnifiers can make reading easier if vision is affected.[14]

The emotional and psychological impact of thyroid eye disease should not be underestimated. Changes in appearance, such as bulging eyes and puffy eyelids, can affect self-esteem and social interactions. Some people may feel self-conscious or anxious about how others perceive them. Seeking support from a counselor or therapist can help patients process these emotions and develop coping strategies. Joining a support group, either in person or online, can provide a sense of community and connection with others who understand the challenges of living with this condition.[14]

Open communication with friends, family, and coworkers about the condition can foster understanding and support. Planning social activities in familiar, comfortable settings and choosing quieter times for outings can reduce anxiety. Practicing stress management techniques such as meditation, yoga, or deep breathing exercises can improve overall well-being and help manage the emotional burden of chronic illness.[14]

⚠️ Important
If you notice sudden changes in your vision, such as loss of color perception, blind spots, or severe eye pain, contact your doctor immediately. These can be signs of compressive optic neuropathy, a serious complication that requires urgent treatment to prevent permanent vision loss.

The Importance of Monitoring and Follow-Up

Regular follow-up with healthcare providers is essential for anyone with thyroid eye disease. This includes both an endocrinologist to manage thyroid function and an ophthalmologist to monitor eye health. During the active phase, appointments may be frequent to track disease progression and adjust treatments as needed. Blood tests to check thyroid hormone levels and antibody levels help guide management decisions.[1]

A clinical activity score may be used to assess the level of inflammation in the eyes. This score is based on symptoms such as pain, redness, swelling, and difficulty with eye movement. Tracking changes in this score over time helps determine whether treatments are working and whether the disease is transitioning from the active to the inactive phase.[3]

Imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI) scans may be performed to evaluate swelling in the eye muscles and tissues behind the eyes. These scans provide detailed images that help doctors understand the extent of the disease and plan surgical interventions if needed.[6]

Ongoing Clinical Trials on Endocrine ophthalmopathy

  • A study to test if atorvastatin can prevent eye disease in patients newly diagnosed with Graves’ disease

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Sweden
  • Study on the Effects of VRDN-003 for Patients with Active Thyroid Eye Disease

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary The Netherlands Poland Spain
  • Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Italy Poland Spain
  • Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland Spain
  • Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary The Netherlands Poland Spain
  • Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland
  • Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria France Germany Italy Latvia +4
  • Study of Efgartigimod for Adults with Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Estonia Germany Greece +4
  • Study of VRDN-001 for Patients with Thyroid Eye Disease Who Did Not Respond to Previous Treatment

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Hungary Italy The Netherlands +2
  • Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

    Not recruiting

    Investigated diseases:
    Investigated drugs:
    Italy Spain

References

https://www.endocrine.org/patient-engagement/endocrine-library/thyroid-eye-disease

https://www.mayoclinic.org/diseases-conditions/graves-disease/symptoms-causes/syc-20356240

https://pmc.ncbi.nlm.nih.gov/articles/PMC5384127/

https://emedicine.medscape.com/article/1218444-overview

https://www.columbiadoctors.org/health-library/condition/hyperthyroidism-graves-ophthalmopathy/

https://www.yourhormones.info/endocrine-conditions/thyroid-eye-disease/

https://www.usz.ch/en/disease/endocrine-orbitopathy/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10113320/

https://www.mayoclinic.org/diseases-conditions/graves-disease/diagnosis-treatment/drc-20356245

https://www.endocrine.org/patient-engagement/endocrine-library/thyroid-eye-disease

https://pmc.ncbi.nlm.nih.gov/articles/PMC9727317/

https://www.everydayhealth.com/thyroid-disease/improving-thyroid-eye-disease-management/

https://my.clevelandclinic.org/health/diseases/17558-thyroid-eye-disease

https://raymonddouglasmd.com/tips-for-adapting-your-life-with-thyroid-eye-disease

FAQ

Can thyroid eye disease cause permanent vision loss?

Yes, in rare severe cases, thyroid eye disease can cause permanent vision loss if the optic nerve becomes compressed by swollen tissues behind the eye. This is called compressive optic neuropathy and requires urgent treatment, often with high-dose steroids or surgical decompression. Most cases of thyroid eye disease are mild and do not result in vision loss, but regular monitoring by an eye specialist is important.

How long does the active phase of thyroid eye disease last?

The active phase of thyroid eye disease typically lasts between nine and twelve months, though this can vary from person to person. During this time, inflammation is most pronounced and symptoms may fluctuate. After the active phase, the disease usually enters an inactive phase where inflammation settles, though some changes in appearance and eye function may remain.

Will my eyes return to normal after treatment?

Some changes may improve or resolve completely after the disease becomes inactive, but others may be permanent. Mild eye bulging, swelling, and redness often improve over time. However, significant eye bulging, eyelid retraction, and double vision may require surgical correction. The extent of recovery depends on the severity of the disease and how quickly treatment was started.

Can I still drive if I have double vision from thyroid eye disease?

Double vision can make driving unsafe and may legally disqualify you from driving until the problem is resolved. Your eye doctor may prescribe special prism glasses to help correct the double vision temporarily. If double vision persists after the disease becomes inactive, strabismus surgery can often correct the eye alignment and restore safe vision for driving.

Is thyroid eye disease hereditary?

Thyroid eye disease itself is not directly inherited, but autoimmune conditions like Graves’ disease do tend to run in families. If you have a family history of autoimmune thyroid disease, you may have a higher risk of developing thyroid eye disease if you develop Graves’ disease. However, many people with thyroid eye disease have no family history of thyroid problems.

🎯 Key Takeaways

  • Thyroid eye disease affects about one-third of people with Graves’ disease, but only 5% develop moderate to severe symptoms requiring intensive treatment.
  • The disease goes through an active inflammatory phase lasting about 9-12 months before settling into an inactive phase.
  • Keeping thyroid hormone levels stable is crucial—both high and low thyroid hormones can worsen eye symptoms.
  • Quitting smoking is the single most important thing patients can do to improve outcomes, as smoking makes the disease seven times more likely and significantly more severe.
  • Intravenous corticosteroids are the first-line treatment for moderate to severe active disease and can prevent vision loss.
  • Teprotumumab, a biologic drug that blocks the IGF-1 receptor, has shown remarkable results in clinical trials, significantly reducing eye bulging and improving double vision.
  • Surgery is usually reserved for the inactive phase of disease and includes orbital decompression, strabismus correction, and eyelid procedures performed in a specific sequence.
  • Simple supportive measures like artificial tears, cool compresses, sleeping with the head elevated, and wearing sunglasses can greatly improve comfort and protect the eyes.